CURRENT POSSIBILITIES OF ORGANIZED SCREENING FOR CANCER OF THE CERVIX UTERI


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To carry out a systematic analysis of the data available in the literature on new possibilities of organized screening for cancer of the cervix uteri (CCU), by applying biological self-sampling for high-risk HPV testing. Materials and methods. The review included the data of foreign and Russian papers published in the electronic databases Medline, PubMed, and Cochrane Library in the past 10 years. Results. The paper describes the results of self-sampling of vaginal discharge for testing, followed by its test for HPV using a PCR assay in different countries of the word as screening for CCU, as well as a comparison of this technique with cytological screening. It shows the efficiency of the test in identifying high-risk HPV types, which determines a possibility for its use in CCU screening programs in Russia. Conclusion. The increase in the incidence of CCU necessitates for a more effective approach to the early diagnosis of this disease. Self-sampling for HPV testing is acceptable for large-scale screening for CCU. The method reduces the cost of the screening, increases its coverage of the population, and has a high sensitivity and specificity. There is a need for further investigations in this area.

Full Text

Restricted Access

About the authors

Inna A. Apolikhina

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University

Email: i_apolikhina@oparina4.ru
MD, Head of Gynecology and aesthetic rehabilitation; professor of the Department of Obstetrics, Gynecology, Perinatology, and Reproductology 117997, Russia, Moscow Ac. Oparina str. 4

Ekaterina Vladimirovna Filippenkova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: e_filippenkova@oparina4.ru
graduate student 117997, Russia, Moscow Ac. Oparina str. 4

Elena Genrichovna Dodova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: adeli575@mail.ru
graduate student 117997, Russia, Moscow Ac. Oparina str. 4

Hasanova Fazilevna Gulnara

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: g_gasanova@oparina4.ru
graduate student 117997, Russia, Moscow Ac. Oparina str. 4

Elena A. Gorbunova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: el_gorbunova@oparina4.ru
doctor in the department of gynecology and aesthetic rehabilitation 117997, Russia, Moscow Ac. Oparina str. 4

References

  1. Абакарова П.Р., Довлетханова Э.Р., Межевитинова Е.А. Значение скрининга в диагностике предрака и рака шейки матки. Эффективная фармакотерапия. 2014; 23: 6-9.
  2. Кулаков В.И., Прилепская В.Н., Паавонен Й. Профилактика рака шейки матки. Руководство для врачей. М.: МЕДпресс-информ; 2008
  3. Прилепская В.Н., Роговская С.И. Возможности Изопринозина в лечении хронических цервицитов и вагинитов. Русский медицинский журнал. 2008; 16(1): 5-9.
  4. WHO. Comprehensive cervical cancer control. A guide to essential practice -Second edition, 2014
  5. Centers for Disease Control and Prevention (CDC). Human papillomavirus-associated cancers-United States, 2004-2008. MMWR Morb. Mortal. Wkly Rep. 2012; 61(15): 258-61.
  6. Chaturvedi A.K., Engels E.A., Pfeiffer R.M., Hernandez B.Y., Xiao W., Kim E. et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J. Clin. Oncol. 2011; 32(29): 4294-301.
  7. Gillison M.L., Chaturvedi A.K., Lowy D.R. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer. 2008; 113(10): 3036-44.
  8. Slatter T.L., Hung N.G., Clow W.M., Royds J.A., Devenish C.J., Hung N.A. A clinicopathological study of episomal papillomavirus infection of the human placenta and pregnancy complications. Mod. Pathol. 2015; 28(10): 1369-82.
  9. Crosby R.A., Hagensee M.E., Vanderpool R., Nelson N., Parrish A., Collins T., Jones N. Community-based screening for cervical cancer: a feasibility study of rural appalachian women. Sex. Transm. Dis. 2015; 42(11): 607-11.
  10. Прилепская В.Н., ред. Патология шейки матки и генитальные инфекции. М.: МЕДпресс-информ; 2008.
  11. Доброхотова Ю.Э., Венедиктова М.Г., Гришин И.И., Саранцев А.Н., Морозова К.В., Луценко Н.Н. Эффективность комплексного подхода к лечению дисплазии эпителия шейки матки умеренной и тяжелой степени на фоне инфицирования вирусом папилломы человека. Фарматека. 2015; 3: 44-7.
  12. Hampson L., Martin-Hirsch P., Hampson I.N. An overview of early investigational drugs for the treatment of human papilloma virus infection and associated dysplasia. Expert Opin. Investig. Drugs. 2015; 24(12): 1529-37.
  13. Andrae B., Kemetli L., Sparén P., Silfverdal L., Strander B., Ryd W. et al. Screening - preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J. Natl. Cancer Inst. 2008; 100(9): 622-9.
  14. Stenvall H., Wikström I., Backlund I., Wilander E. Accuracy of HPV testing of vaginal smear obtained with a novel self-sampling device. Acta Obstet. Gynecol. Scand. 2007; 86(1): 16-21.
  15. II Междисциплинарный форум с международным участием «Шейка матки и вульвовагинальные болезни». ВПЧ-тест - самостоятельно, доступно и при этом в сертифицированной лаборатории. Реальность XXI века. Эффективная фармакотерапия. 2014; 5: 43-9.
  16. Mayrand M.H., Duarte-Franco E., Rodrigues I., Walter S.D., Hanley J., Ferenczy A. et al.; Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 2007; 357(16): 1579-88.
  17. Mayrand M.H., Duarte-Franco E., Coutlée F., Rodrigues I., Walter S.D., Ratnam S., Franco E.L.; CCCaST Study Group. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial. Int. J. Cancer. 2006; 119(3): 615-23.
  18. Sanner K., Wikström I., Strand A., Lindell M., Wilander E. Self-sampling of the vaginal fluid at home combined with high-risk HPV testing. Br. J. Cancer. 2009; 101(5): 871-4.
  19. Sancho-Garnier H., Tamalet C., Halfon P., Leandri F.X., Le Retraite L., Djoufelkit K. et al. HPV self-sampling or the Pap-smear: a randomized study among cervical screening nonattenders from lower socioeconomic groups in France. Int. J. Cancer. 2013; 133(11): 2681-7.
  20. Penaranda E., Molokwu J., Flores S., Byrd T., Brown L., Shokar N. Women’s attitudes toward cervicovaginal self-sampling for high-risk HPV infection on the US-Mexico border. J. Low. Genit. Tract. Dis. 2015; 19(4): 323-8.
  21. Jentschke M., Chen K., Arbyn M., Hertel B., Noskowicz M., Soergel P., Hillemanns P. Comparative evaluation of two vaginal self-sampling devices for the detection of human papillomavirus infections. J. Clin. Virol. 2016; 82: 46-50.
  22. Racey C.S., Withrow D.R., Gesink D. Self-collected HPV testing improves participation in cervical cancer screening: a systematic review and meta-analysis. Can. J. Public Health. 2013; 104(2): e159-65.
  23. Darlin L., Borgfeldt C., Forslund O., Hénic E., Hortlund M., Dillner J., Kannisto P. Comparison of use of vaginal HPV self-sampling and offering flexible appointments as strategies to reach long-term non-attending women in organized cervical screening. J. Clin. Virol. 2013; 58(1): 155-60.
  24. Wikström I., Lindeil M., Sanner K., Wilander E. Self-sampling and HPV testing or ordinary Pap-smear in women not regularly attending screening: a randomised study. Br. J. Cancer. 2011; 105(3): 337-9.
  25. Eperon I., Vassilakos P., Navarria I., Menoud P.A., Gauthier A., Pache J.C. et al. Randomized comparison of vaginal self-sampling by standard vs. dry swabs for human papillomavirus testing. BMC Cancer. 2013; 13: 353-9.
  26. Pathak N., Dodds J., Zamora J., Khan K. Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. BMJ. 2014; 349: g5264.
  27. Östensson E., Fröberg M., Leval A., Hellström A.-C., Bäcklund M., Zethraeus N., Andersson S. Cost of preventing, managing, and treating human papillomavirus (HPV)-related diseases in Sweden before the introduction of quadrivalent HPV vaccination. PLoS One. 2015; 10(9): e0139062.
  28. Zhu J., Norman I., Elfgren K., Gaberi V., Hagmar B., Hjerpe A., Andersson S. A comparison of liquid-based cytology and Pap smear as a screening method for cervical cancer. Oncol. Rep. 2007; 18(1): 157-60.
  29. Adamson P.C., Huchko M.J., Moss A.M., Kinkel H.F., Medina-Marino A. Acceptability and accuracy of cervical cancer screening using a self-collected tampon for HPV messenger-RNA testing among HIV-infected women in South Africa. PLoS One. 2015; 10(9): e0137299.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies